Springer Health+ IME (@SpringerIME)
@SpringerIME
Springer Health+ IME, providing independent medical education in Neurology, Diabetes, Oncology, Rare Diseases, Endocrinology, and Paediatrics.
2.8K 正在关注 19.9K 粉丝
Are you exploring how to set up an amyloidosis center in Latin America? Join our roundtable virtual meeting for region-specific insights from experts who have established a successful center.
Are you exploring how to set up an amyloidosis center in Latin America? Join our virtual roundtable meeting to discuss country‑specific challenges, exchange insights, and begin building a supportive professional network.
显示更多
Explore the clinical data supporting available and emerging treatment options for NTRK fusion-positive NSCLC with this free, downloadable case study—ready to use in your clinical practice.
Are rare fusions still off your radar in NSCLC?
Download this free, print-ready case study, exploring the clinical data supporting available and emerging treatments for NTRK fusion-positive NSCLC.
Get best practices for identifying rare fusions in NSCLC with this free, downloadable case study—ready to use in your clinical practice.
How confident are you that you'd catch an NTRK fusion in NSCLC?
Download this free, print-ready case study, covering best practices for biomarker testing to identify NTRK fusions.
Prof. Carola Dröge and Prof. Verena Keitel-Anselmino speak live from EASL 2026, discussing IBAT inhibitor therapy in adults with hereditary BSEP-deficiency.
Live from EASL 2026: Intrahepatic cholestasis of pregnancy recurs in 4 in 10 pregnancies.
Dr Jeremy Nayagam speaks live from EASL 2026, highlighting research on genetic testing in adults with unexplained cholestatic liver disease and hepatitis.
Watch the full video now, and explore our coverage of the congress.
显示更多
Live from EASL 2026: Researchers call for ICP to be included in hepatobiliary risk stratification.
From emerging therapies to tactics for multidisciplinary collaboration, this free, CME-accredited video podcast series combines expert insights with the latest scientific data to increase your clinical confidence in the management of generalized myasthenia gravis.
显示更多
New phase 2 trial findings published in The Lancet Diabetes & Endocrinology suggest burosumab treatment for X-linked hypophosphataemia (XLH) may begin in the first year of life. Unpick the findings in our latest article.
显示更多
